Abstract
AbstractThe COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.
Publisher
Springer Science and Business Media LLC
Reference68 articles.
1. Cancer Research UK. Cancer in the UK 2019. London: Cancer Research UK; 2019.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–74.
3. Perez-Garcia JL, Awada A, Calvo E, Amaral T, Akenau HT, Gruenwald V, et al. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open. 2020;5:e000662.
4. CRUK, ECCO, EORTC, ECRIN, ESMO, ESF, et al. Revision of the EU Clinical Trials Directive: A joint statement from non-commercial and commercial organisations. London: Cancer Research UK; 2013.
5. Rawlins M. A new era for UK clinical research? Lancet 2011;377:190–2.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献